TRAF6 upregulates expression of HIF-1α and promotes tumor angiogenesis

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4950-4959

  Sun, Heng ^a   Li, Xue Bing ^a,c   Meng, Ya ^a   Fan, Li ^a   Li, Min ^b   Fang, Jing ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; OXYGEN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VASCULARIZATION; UBIQUITINATION; UPREGULATION; UTERINE CERVIX CANCER;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSFECTION; UP-REGULATION;

EID: 84881401763     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0370     Document Type: Article

References (38)

1. Keith B, Johnson RS, Simon MC. HIF1a and HIF2a: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011;12: 9-22.
2. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
3. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393-410.
4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
5. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
6. Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012;246:95-106.
7. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-kB regulatory pathways. Annu Rev Biochem 2009;78:769-96.
8. Choi Y. Role of TRAF6 in the immune system. Adv Exp Med Biol 2005; 560:77-82.
9. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001;20:6482-91.
10. Hostager BS. Roles of TRAF6 in CD40 signaling. Immunol Res 2007;39:105-14.
11. Darnay BG, Besse A, Poblenz AT, Lamothe B, Jacoby JJ. TRAFs in RANK signaling. Adv Exp Med Biol 2007;597:152-9.
12. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010;16:49-58.
13. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copynumber alteration across human cancers. Nature 2010;463:899-905.
14. Starczynowski DT, Lockwood WW, Delehouzee S, Chari R, Wegrzyn J, Fuller M, et al. TRAF6 is an amplified oncogene bridging the RAS and NF-kB pathways in human lung cancer. J Clin Invest 2011;121: 4095-105.
15. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
16. Frede S, Berchner-Pfannschmidt U, Fandrey J. Regulation of hypoxiainducible factors during inflammation. Methods Enzymol 2007;435: 405-19.
17. Zucchelli S, Codrich M, Marcuzzi F, Pinto M, Vilotti S, Biagioli M, et al. TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alphasynuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains. Hum Mol Genet 2010;19:3759-70.
18. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem 2007;282:4102-12.
19. Xue J, Lv DD, Jiao S, Zhao WT, Li XB, Sun H, et al. pVHL mediates K63- linked ubiquitination of nCLU. PLoS ONE 2012;7:e35848.
20. Fu BB, Xue J, Li ZD, Shi X, Jiang BH, Fang J. Chrysin inhibits expression of HIF-1a through reducing HIF-1a stability and inhibiting its protein synthesis. Mol Cancer Ther 2007;6:220-6.
21. Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J. Prolyl hydroxylase-3 is downregulated in colorectal cancer cells and inhibits IKKb, independent of hydroxylase activity. Gastroenterology 2010;138: 606-15.
22. Hu XW, Meng D, Fang J. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase. Carcinogenesis 2008;29:2369-76.
23. Luo W, Zhong J, Chang R, Hu H, Pandey A, Gregg Semenza L. Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia- inducible factor (HIF)-1a but not HIF-2a. J Biol Chem 2010;285: 3651-63.
24. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O (2)-independent and HSP90 inhibitor-induced degradation of HIF- 1alpha. Mol Cell 2007;25:207-17.
25. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated upregulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003;17:2115-7.
26. Rius J,GumaM, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NF-kB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1a. Nature 2008;453:807-12.
27. Elmetwali T, Young LS, Palmer DH. CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals. J Immunol 2010;184:1111-20.
28. Zapata JM, Krajewska M, Krajewski S, Krajewski S, Kitada S, Welsh K, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000;165:5084-96.
29. Rajandram R, Bennett NC, Morais C, Johnson DW, Gobe GC. Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins. Med Hypotheses 2012;78:330-6.
30. Starska K, Forma E, Lewy-Trenda I, Stasikowska O, Brys M, Krajewska WM, et al. The expression of SOCS1 and TLR4-NFkappaB pathway molecules in neoplastic cells as potential. Folia Histochem Cytobiol 2009;47:401-10.
31. Hirata Y, Ohmae T, Shibata W, Maeda S, Ogura K, Yoshida H, et al. MyD88 and TNF receptor-associated factor 6 are critical signal transducers in Helicobacter pylori-infected human epithelial cells. J Immunol 2006;176:3796-803.
32. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, et al. Contribution of IL-17-producing gammadeltaTcells to the efficacy of anticancer chemotherapy. J Exp Med 2011;208:491-503.
33. Ma T, Wang N, Su Z, Chen L, Zhu N, Ma C, et al. Characterization of apoptosis and proliferation in esophageal carcinoma EC109 cells following siRNA-induced down-regulation of TRAF6. Mol Cell Biochem 2011b;352:77-85.
34. Page EL, Robitaille GA, Pouyssegur J, Richard DE. Induction of hypoxia-inducible factor 1a by transcriptional and translational mechanisms. J Biol Chem 2002;277:48403-9.
35. Elsasser S, Finley D. Delivery of ubiquitinated substrates to proteinunfolding machines. Nat Cell Biol 2005;7:742-9.
36. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, et al. The E3 ligase TRAF6 regulates AKT ubiquitination and activation. Science 2009;325:1134-8.
37. Schirbel A, Kessler S, Rieder F, West G, Rebert N, Asosingh K, et al. Pro-angiogenic activity of TLRs and NLRs: a novel link between Gut microbiota and intestinal angiogenesis. Gastroenterology 2013;144: 613-23.
38. Peng Z, Shuangzhu Y, Yongjie J, Xinjun Z, Ying L. TNF receptorassociated factor 6 regulates proliferation, apoptosis, and invasion of glioma cells. Mol Cell Biochem 2013;377:87-96.